
SMTI Valuation
Sanara Medtech Inc
- Overview
- Forecast
- Valuation
- Earnings
SMTI Relative Valuation
SMTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SMTI is overvalued; if below, it's undervalued.
Historical Valuation
Sanara Medtech Inc (SMTI) is now in the Fair zone, suggesting that its current forward PS ratio of 2.22 is considered Fairly compared with the five-year average of -9.68. The fair price of Sanara Medtech Inc (SMTI) is between 30.10 to 91.30 according to relative valuation methord.
Relative Value
Fair Zone
30.10-91.30
Current Price:31.92
Fair
-22.09
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Sanara Medtech Inc. (SMTI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 3.21. The thresholds are as follows: Strongly Undervalued below -25.11, Undervalued between -25.11 and -10.95, Fairly Valued between 17.37 and -10.95, Overvalued between 17.37 and 31.52, and Strongly Overvalued above 31.52. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-42.54
EV/EBIT
Sanara Medtech Inc. (SMTI) has a current EV/EBIT of -42.54. The 5-year average EV/EBIT is -18.58. The thresholds are as follows: Strongly Undervalued below -142.04, Undervalued between -142.04 and -80.31, Fairly Valued between 43.15 and -80.31, Overvalued between 43.15 and 104.88, and Strongly Overvalued above 104.88. The current Forward EV/EBIT of -42.54 falls within the Historic Trend Line -Fairly Valued range.
2.58
PS
Sanara Medtech Inc. (SMTI) has a current PS of 2.58. The 5-year average PS is 4.50. The thresholds are as follows: Strongly Undervalued below -0.82, Undervalued between -0.82 and 1.84, Fairly Valued between 7.16 and 1.84, Overvalued between 7.16 and 9.82, and Strongly Overvalued above 9.82. The current Forward PS of 2.58 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Sanara Medtech Inc. (SMTI) has a current P/OCF of 0.00. The 5-year average P/OCF is 37.17. The thresholds are as follows: Strongly Undervalued below -458.56, Undervalued between -458.56 and -210.70, Fairly Valued between 285.03 and -210.70, Overvalued between 285.03 and 532.90, and Strongly Overvalued above 532.90. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Sanara Medtech Inc. (SMTI) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Sanara Medtech Inc (SMTI) has a current Price-to-Book (P/B) ratio of 7.75. Compared to its 3-year average P/B ratio of 7.12 , the current P/B ratio is approximately 8.85% higher. Relative to its 5-year average P/B ratio of 10.44, the current P/B ratio is about -25.76% higher. Sanara Medtech Inc (SMTI) has a Forward Free Cash Flow (FCF) yield of approximately -0.94%. Compared to its 3-year average FCF yield of -1.35%, the current FCF yield is approximately -30.51% lower. Relative to its 5-year average FCF yield of -1.67% , the current FCF yield is about -43.79% lower.
7.75
P/B
Median3y
7.12
Median5y
10.44
-0.81
FCF Yield
Median3y
-1.35
Median5y
-1.67
Competitors Valuation Multiple
The average P/S ratio for SMTI's competitors is 2.92, providing a benchmark for relative valuation. Sanara Medtech Inc Corp (SMTI) exhibits a P/S ratio of 2.58, which is -11.44% above the industry average. Given its robust revenue growth of 28.14%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SMTI decreased by 15.30% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 20.16M to 25.83M.
The secondary factor is the P/E Change, contributed 11.96%to the performance.
Overall, the performance of SMTI in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch

DOMO
Domo Inc
14.140
USD
-1.81%

IMMP
Immutep Ltd
1.720
USD
-0.58%

AQST
Aquestive Therapeutics Inc
4.110
USD
+2.49%

RZLT
Rezolute Inc
6.460
USD
-0.15%

GAU
Galiano Gold Inc
1.940
USD
+22.78%

AVIR
Atea Pharmaceuticals Inc
3.490
USD
-0.29%

FPH
Five Point Holdings LLC
5.550
USD
-0.36%

ARQ
Arq Inc
7.360
USD
-4.79%

RGP
Resources Connection Inc
4.720
USD
-4.26%

BRBS
Blue Ridge Bankshares Inc
3.740
USD
-1.32%
FAQ

Is Sanara Medtech Inc (SMTI) currently overvalued or undervalued?
Sanara Medtech Inc (SMTI) is now in the Fair zone, suggesting that its current forward PS ratio of 2.22 is considered Fairly compared with the five-year average of -9.68. The fair price of Sanara Medtech Inc (SMTI) is between 30.10 to 91.30 according to relative valuation methord.

What is Sanara Medtech Inc (SMTI) fair value?

How does SMTI's valuation metrics compare to the industry average?

What is the current P/B ratio for Sanara Medtech Inc (SMTI) as of Aug 15 2025?

What is the current FCF Yield for Sanara Medtech Inc (SMTI) as of Aug 15 2025?

What is the current Forward P/E ratio for Sanara Medtech Inc (SMTI) as of Aug 15 2025?
